FDA advisers back Moderna’s 50+ flu mRNA vaccine, tipping toward the first seasonal shot
A Thursday vote supports Moderna’s benefits-over-risks case, raising odds the first mRNA-based seasonal influenza vaccine lands soon.
By Mohammed Al-Shehri·· 3 min